Occlutech is a leading provider of minimally invasive structural heart disease devices. Occlutech develops, manufactures, and commercializes structural heart and interatrial shunt products to improve the treatment of patients.
Occlutech has a broad and proven portfolio, with more than 130,000 products sold, addressing congenital defects, stroke prevention, and heart failure.
Occlutech markets and sells its structural heart and interatrial shunt products to hospitals and clinics in over 80 countries through its direct sales organization and international network of distribution partners.
Occlutech maintains manufacturing and R&D facilities in Jena, Germany and Istanbul, Turkey, with a global supply and customer support hub located in Helsingborg, Sweden.
Occlutech combines several base technologies and expertise to create state-of-the-art cardiac and vascular implants. Technologies have been developed and patented by Occlutech to make a difference and allow better treatment of patients around the world. Occlutech wants to be at the forefront of new technologies and our R&D teams spend a lot of time discussing new treatment options for current and new therapeutic areas in the rapidly developing structural heart disease area.